

Review Article

Caco-2 models for xenobiotic metabolism and transportation

Nathaphon Kuncharoenwirat¹, Waranya Chatuphonprasert², and Kanokwan Jarukamjorn^{1*}

¹ *Research Group for Pharmaceutical Activities of Natural Products using Pharmaceutical Biotechnology (PANPB), Faculty of Pharmaceutical Sciences, Khon Kaen University, Mueang, Khon Kaen, 40002 Thailand*

² *Faculty of Medicine, Mahasarakham University, Mueang, Maha Sarakham, 44000 Thailand*

Received: 28 September 2020; Revised: 14 September 2022; Accepted: 16 September 2022

Abstract

The intestine plays an important role in the absorption, metabolism, and transportation of xenobiotics including drugs and foods. Therefore, an *in vitro* intestinal model for predicting bioavailability of xenobiotics is important for the drug and food industries. Caco-2 is a human colon carcinoma cell line widely employed as a model to represent xenobiotic absorption, transportation, and metabolism in the human intestinal tract. However, Caco-2 has limitations as an intestinal model due to the low expression of metabolizing enzymes and the long time period required for cell differentiation. Hence, several modified Caco-2 models have been developed to overcome these limitations and to establish Caco-2 models that correlate well with human intestine. These include xenobiotic-induced cytochrome P450 and transporter expression models, nuclear receptor gene-modified Caco-2 cells, and a novel Caco-2 culturing method that mimics the physiological characteristics of the human intestine and accelerates the growth rate of Caco-2.

Keywords: colon carcinoma cell, Caco-2, cytochrome P450, transporter, intestinal model

1. Introduction

Drugs and nutrients mainly enter into the body by oral administration (Ferrec & Fardel, 2012). The intestine is considered a large surface area organ for food and drug absorption according to its very long length and plentiful supply of microvillus on the surface of enterocytes (Kaminsky & Zhang, 2003). Likewise, the intestine plays a role in xenobiotic metabolism and transportation, which affect xenobiotics entering the blood circulation system (Kaminsky & Zhang, 2003; Vaessen *et al.*, 2017). Therefore, predicting absorption, permeation, transportation, and metabolism of xenobiotics using intestinal models is important (Vaessen *et al.*, 2017).

Caco-2 is a human colon carcinoma cell line (Rousset, 1986) that is widely used as a model of the intestinal barrier for examination of drug and xenobiotic permeation,

metabolism, and transportation due to its good correspondence with human intestinal morphology (Boulenc *et al.*, 1992; Meunier, Bourrié, Berger, & Fabre, 1995; Natoli *et al.*, 2011; Vaessen *et al.*, 2017). Despite being a human colorectal carcinoma cell line, Caco-2 has a spontaneous differentiation property that provides a morphology more like a small intestinal enterocyte than other colorectal carcinoma cell lines (Borlak & Zwadlo, 2003; Maubon *et al.*, 2007). However, Caco-2 has limitations as an intestinal model. For instance, Caco-2 expresses only intestinal enterocyte morphology, while the human intestine is composed of several cell types, e.g. Paneth cells, enteroendocrine cells, and goblet cells (Ferrec & Fardel, 2012; Lea, 2015). Caco-2 also exhibits low expression of cytochrome P450 (CYP) oxidative metabolizing enzymes and does not display other physiological factors that influence xenobiotic uptake and transportation, such as mucus on the small intestinal surface and movement of fluid in the lumen (Lea, 2015). Therefore, several culturing methods have been developed to modify the Caco-2 models to suit specific study purposes (Küblbeck *et al.*, 2016; Lea, 2015; Li, Sai, Kato, Tamai, & Tsuji, 2003; Sun, Chow, Liu, Du, & Pang, 2008).

*Corresponding author

Email address: kanok_ja@kku.ac.th

2. Xenobiotic-Induced Monolayer Caco-2 Models

CYPs and transporters are regulated by transcriptional processes through ligand-activated nuclear receptors including the aryl hydrocarbon receptor (AhR), the constitutive androstane receptor (CAR), and the pregnane X receptor (PXR) (Guengerich, 2013; Zanger & Schwab, 2013). Generally, an inducer will bind to its specific nuclear receptor to form an inducer-receptor complex before it dimerizes with a specific nuclear translocase such as the AhR nuclear translocator (ARNT), the retinoid X receptor (RXR), and the glucocorticoid receptor (GR). The activated dimeric complex subsequently binds to a specific response element on the CYP or transporter gene, resulting in an increase in transcriptional expression (Guengerich, 2013). There are many clinical drugs and substances, such as Aroclor 1254, rifampicin, dexamethasone, phenobarbital, carbamazepine, tenofovir, and efavirenz, that can be used as inducers to examine expression and activity of CYPs and transporters (Borlak & Zwadlo, 2003; Boulenc *et al.*, 1992; Brück, Strohmeier, Busch, Drozdik, & Oswald, 2017; Mukhopadhyaya *et al.*, 2016). These clinical drugs and substances have been employed in Caco-2 monolayers to predict the impact of related substances on CYPs and transporters in human intestine (Ferrec & Fardel, 2012; Lea, 2015; Li *et al.*, 2003).

Aroclor 1254, a typical CYP inducer, is a polychlorinated biphenyl compound. Aroclor 1254 induces CYP1A via the AhR-ARNT signaling pathway (Borlak & Zwadlo, 2003; Guengerich, 2013), while CYP2 and CYP3 are induced via the retinoic acid receptor (RAR)-RXR pathway. It remains unclear which pathway Aroclor 1254 uses to mediate its interactions with ATP-binding cassette (ABC) transporters (Borlak & Zwadlo, 2003). Aroclor 1254 was used to induce CYPs and transporters in Caco-2 from Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany (Caco-2/DSMZ). The cells were subcultured every 5 to 6 days until the fifth passage, and then they were divided into 3 groups, including control and cells treated with Aroclor 1254 (10 µM) for 24 and 72 hours (Borlak & Zwadlo, 2003). Aroclor 1254 did not change Caco-2 morphology while it induced expression of *CYP1A1*, *CYP1A2*, *CYP2C*, *CYP2E1*, and *CYP3A5* by 2.4 to 80 fold. *CYP1A2* showed the highest expression after the 72 hour-treatment while *CYP2E1* exhibited the lowest expression with the 24 hour-treatment. Expression of *CYP2D6* was decreased by Aroclor 1254, while *CYP3A4* and *CYP2B6/7* were not detected. Regarding the transporters, Aroclor 1254 elevated expression of ABC subfamily B member 1 (*ABCB1*), *ABCC1*, *ABCC3*, *ABCC4*, and *ABCC5* with the highest induction at 24 hours (Table 1) (Borlak & Zwadlo, 2003).

Caco-2 (INSERM U-178, Villejuif, France) at passages no. 72 to 98 were cultured for 35 days before treatment for 3 days with typical CYP inducers acting via AhR (50 µM β-naphthoflavone, 50 µM 3-methylcholanthrene, 100 µM isosafrole, and 1 nM dioxin), PXR (50 µM rifampicin), CAR (2 mM phenobarbital), and GR (50 µM dexamethasone) (Boulenc *et al.*, 1992; Zanger & Schwab, 2013). Isosafrole and phenobarbital did not induce *CYP1A1* and *CYP1A2* expression while 3-methylcholanthrene, dioxin, and β-naphthoflavone extensively induced expression of *CYP1A1* (Table 1) (Boulenc *et al.*, 1992). Caco-2 (Leibniz

Institute DSMZ-German Collection of Microorganisms and Cell Cultures) at passages no. 16 to 19 were cultured for 21 days before incubation for 48 hours with carbamazepine (500 µM), efavirenz (10 µM), hypericin (0.5 µM) plus hyperforin (1 µM), or rifampicin (100 µM), which induce expression of ABC, solute carrier organic anion (SLCO) or solute carrier (SLC) transporters through the PXR-RXR signaling pathway (Brück *et al.*, 2017). Expression of *ABCB1*, *ABCC2*, *ABCG2*, SLCO family member 2B1 (*SLCO2B1*), and SLC family member 15A1 (*SLC15A1*) mRNAs and proteins were not modified by the treatments (Table 1).

To further determine activity of a major efflux transporter *ABCB1*, Caco-2 was seeded in a transwell-plate with polyethylene terephthalate (PET) filter membrane insert for 21 days before treatment for 48 hours with carbamazepine (500 µM), efavirenz (10 µM), hypericin (0.5 µM) plus hyperforin (1 µM), or rifampicin (100 µM). The efflux ratio of digoxin and talinolol (substrates of *ABCB1*) was not changed, but a significant decrease was found after co-treatment with an *ABCB1* inhibitor, valsopodar (PSC833; 10 µM) (Table 2) (Brück *et al.*, 2017). Seeding of Caco-2/ATCC at passage no. 30 to 60 in a collagen coated plate was suitable for determining expression of *CYP3A4* and transporters (*ABCB1*, *ABCC2*, *ABCC3*, and *SLC15A1*) while seeding in a transwell-plate with polycarbonate (PC) filter membrane insert was fit for examining *ABCB1* activity. The Caco-2/ATCC cells were cultured for 14 days, then treated for 72 hours with the following tested compounds (10 µM); all-*trans* retinoic acid (ATRA, which acts via an RAR-RXR ligand to induce *CYP3A* and *ABCB1* expression), rifampicin and paclitaxel (typical inducers of *CYP3A* and *ABCB1* expression that act through the steroid xenobiotic receptor (SXR) or PXR pathways), progesterone and quercetin (SLC and ABC transporter-stimulators that act via the progesterone and estrogen receptors) (Notas *et al.*, 2012; Li *et al.*, 20; Zanger & Schwab, 2013), or ascorbic acid (10 µM), or *L*-Lysine (20 mM) (Li *et al.*, 2003). Quercetin significantly increased expression of *SLC15A1* and *ABCC3* while ATRA significantly elevated expression of *ABCB1* and *CYP3A4*. Ascorbic acid and *L*-lysine increased *CYP3A4* expression (Table 1). Ascorbic acid and *L*-lysine were not involved in the nuclear receptor regulatory mechanism, but might be crucial co-factors for CYP expression (Li *et al.*, 2003; Belin, Kaya, Burtey & Fontes, 2010). For *ABCB1* activity, after seeding Caco-2 in a transwell-plate for 24 days, the differentiated Caco-2 cells were treated for 72 hours with ATRA (10 µM). Then the cells were incubated with [³H]-digoxin (a *ABCB1* substrate) and [¹⁴C]-mannitol (a paracellular transporter reference marker) and the digoxin permeability ratio was calculated. ATRA significantly elevated the digoxin permeability ratio, which represented an increase in *ABCB1* activity (Table 2) (Li *et al.*, 2003).

Anti-retroviral drugs can cause drug interactions and clinical problems by interfering with drug transportation, especially in the main absorption site (the intestine), and affecting drug bioavailability (Foy, Sperati, Lucas, & Estrella, 2014; Mukhopadhyaya *et al.*, 2016). Intestinal transporters, particularly *ABCB1*, are normally regulated via the PXR signaling pathway, therefore exposure to protease inhibitor antiretroviral drugs can induce expression of *ABCB1* transporters (Gupta *et al.*, 2008). Caco-2 (Health Protection

Table 1. Xenobiotic-induced Caco-2 monolayer models for the conventional culturing method

Caco-2 origins		Treatment substances (concentration/incubation time)	Results	References
Caco-2/ DSMZ	25 cm ² flask	Aroclor 1254 (10 µM/24, 72 h)	↑ <i>CYP1A1, CYP1A2, CYP2C, CYP2E1, CYP3A5, ABCB1, ABCC1, ABCC3, ABCC4, ABCC5</i> ↓ <i>CY2D6</i>	Borlak & Zwadlo, 2003
Caco-2/ Pr. A. Zweibaum	180 cm ² flask	Dioxin (1 nM/72 h) β-naphthoflavone (50 µM/72 h) 3-methylcholanthene (50 µM/72 h) Phenobarbital (2 mM/72 h) Isosafrole (100 µM/72 h) Rifampicin (50 µM/72 h) Dexamethasone (50 µM/72 h)	↑ <i>CYP1A1</i> – <i>CYP1A1, CYP1A2</i> ↑ <i>CYP1A1, CYP1A2</i>	Boulenc <i>et al.</i> , 1992
Caco-2/ ATCC	6-well-plate	Quercetin (10 µM/72 h) ATRA (10 µM/72 h) Ascorbic acid (10 µM/72 h) L-Lysine (20 mM/72 h) Rifampin (10 µM/72h) Paclitaxel (10 µM/72h) Progesterone (10 µM/72 h)	↑ <i>SLC15A1, ABCC3</i> ↑ <i>ABCB1, CYP3A4</i> ↑ <i>CYP3A4</i> – <i>CYP3A4, SLC15A1, ABCB1, ABCC2, ABCC3</i>	Li <i>et al.</i> , 2003
Caco-2/ DSMZ	6-well-plate	Carbamazepine (500 µM/48 h) Efavirenz (10 µM/48 h) Hypericin (0.5 µM) + hyperforin (1 µM)/48 h Rifampicin (100 µM/48 h)	– <i>ABCB1, ABCC2, ABCG2, SLCO2B1, SLC15A1</i>	Brück <i>et al.</i> , 2017

Note: ATCC, American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen; ATRA, all-trans retinoic acid; (↑) increase, (↓) decrease, and (–) no change of expression/activity

Table 2. Xenobiotic-induced Caco-2 monolayer models for the inserted plate-Caco-2 culturing system

Caco-2 origins		Treatment substances (concentration/incubation time)	Results	References
Caco-2/ ATCC	24-transwell-plate with PC filter membrane insert	ATRA (10 µM/72 h)	↑ <i>ABCB1</i> activity	Li <i>et al.</i> , 2003
Caco-2/ DSMZ	24-transwell-plate with PET filter membrane insert	Carbamazepine (500 µM/48 h) Efavirenz (10 µM/48 h) Hypericin (0.5 µM) + hyperforin (1 µM)/48 h Rifampicin (100 µM/48 h) Carbamazepine (500 µM/48 h) + Valspodar (PSC833, 10 µM) Efavirenz (10 µM/48 h) Hypericin (0.5 µM) + hyperforin (1 µM)/48 h Rifampicin (100 µM/48 h)	– <i>ABCB1</i> activity ↓ <i>ABCB1</i> activity	Brück <i>et al.</i> , 2017
Caco-2/ HPA	24-transwell-plate with PC filter membrane insert	Tenofovir (5 mM/72 h) Darunavir (250 µM/72 h) Dapivirin (10 µM/72 h)	↑ <i>SLC7A5, SLC2A1, MVP, ABCC5</i> ↓ <i>SLC15A2, SLC7A9, ABCA1, AQP1</i> ↓ <i>ABCC1, SLC15A2</i> ↓ <i>ABCA1</i> ↑ <i>SLC3A2</i>	Mukhopadhyaya <i>et al.</i> , 2016
Caco-2/ ATCC	12-transwell-plate with Matrigel coated Teflon membrane insert	1α,25-Dihydroxyvitamin D3(0.05 - 1 µM/2 wk) 25-(OH)-D3 (0.05 - 10 µM/2wk) 25-(OH)-D3 (15 - 20 µM/2 wk) Vitamin D3 (0.05 - 1 µM/2 wk)	↑ <i>CYP3A4, CYP3A5</i> [dose dependent] ↑ <i>CYP3A</i> [dose dependent] ↓ <i>CYP3A</i> – <i>CYP3A</i>	Schmiedlin-Ren <i>et al.</i> , 1997

Note: ATCC, American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen; HPA, Health Protection Agency culture collections; ATRA, all-trans retinoic acid; (↑) increase, (↓) decrease, and (–) no change of expression/activity

Agency culture collections, Salisbury, UK) was cultured in a transwell-plate with PC filter membrane insert for 21 days before treatment for 72 hours with 3 anti-retroviral drugs, i.e. tenofovir (5 mM), darunavir (250 μ M), and dapivirin (10 μ M). Tenofovir elevated expression of *SLC7A5*, *SLC2A1*, major vault protein (*MVP*), and *ABCC5*, while *SLC15A2*, *SLC7A9*, *ABCA1*, and aquaporin 1 (*AQP1*) expressions were decreased. Darunavir decreased *ABCC1* and *SLC15A2* expression while dapivirin reduced *ABCA1* expression with an increase in *SLC3A2* expression (Table 2) (Mukhopadhyaya *et al.*, 2016).

A vitamin D derivative, $1\alpha,25$ -dihydroxyvitamin D₃, increased CYP3A4 activity in Caco-2 (Sambuy *et al.*, 2005) resulting in an increase in 1'-hydroxymidazolam, a midazolam metabolite, which is a specific marker for CYP3A4 activity (Sambuy *et al.*, 2005; Schmiedlin-Ren *et al.*, 1997). A vitamin D derivative can increase expression of CYP3A through dimerization of the vitamin D receptor and RXR, followed by binding at the vitamin D response element of the *CYP3A* promoter, resulting in elevation of *CYP3A* transcription (Schmiedlin-Ren *et al.*, 1997). Caco-2 (Caco-2/ATCC, HTB-37, passage no. 24 to 27) was cultured in a transwell-plate with matrigel coated Teflon membrane insert. The cells were incubated for 2 weeks with different concentrations of $1\alpha,25$ -dihydroxyvitamin D₃, vitamin D₃ (0.05 to 1 μ M), and 25-hydroxyvitamin D₃ (25-(OH)-D₃; 0.05 to 20 μ M). All concentrations of $1\alpha,25$ -dihydroxyvitamin D₃ induced expression of *CYP3A4* mRNA while *CYP3A5* expression was slightly induced in a concentration-dependent pattern. Expression of *CYP3A* protein and *CYP3A* catalytic activity were examined (Schmiedlin-Ren *et al.*, 1997). Incubation of Caco-2 with $1\alpha,25$ -dihydroxyvitamin D₃ (0.05 μ M) for 2 weeks induced expression of *CYP3A* protein. On the other hand, 25-(OH)-D₃ induced expression of *CYP3A* protein in a concentration-dependent pattern but those increased expressions were reduced by higher concentrations (15 and 20 μ M). In addition, *CYP3A* catalytic activity was evaluated by incubation of midazolam (4 μ M) in an apical chamber for 6 hours, followed by determination of 1'-hydroxymidazolam metabolite in the apical and basolateral chambers. Incubation of Caco-2 with 25-(OH)-D₃ and $1\alpha,25$ -dihydroxyvitamin D₃ for 2 weeks increased *CYP3A* catalytic activity in a dose-dependent pattern, except at the two higher concentrations (15 and 20 μ M), where they were reduced, which was seen in a decrease in the 1'-hydroxymidazolam level in the apical chamber. Hence, $1\alpha,25$ -dihydroxyvitamin D₃ possessed the highest induction potential due to the highest amount of 1'-hydroxymidazolam found in the apical chamber. In contrast, vitamin D₃ did not alter *CYP3A* (Table 2) (Schmiedlin-Ren *et al.*, 1997).

3. Genetically Modified Caco-2 Models

Levels of CYP mRNA in Caco-2 cells are usually lower than in intact intestinal cells. Expression of *CYP1A*, *CYP2C*, *CYP2D*, *CYP2E*, *CYP2J*, and *CYP3A* was approximately 5-fold lower in Caco-2 cells than in intact human jejunum cells (Vaessen *et al.*, 2017), while *CYP2A*, *CYP2C*, *CYP2D*, *CYP2J2*, *CYP3A4*, and *CYP4F2* expression was 3-fold lower in Caco-2 cells than in intact human duodenal cells (Sun *et al.* 2002). Therefore, the major limitation of Caco-2 is low CYP expression (Korjamo *et al.*, 2006; Küblbeck *et al.*, 2016; Sun *et al.*, 2008). Modulation of

CYP expression is mediated by specific ligands activating nuclear receptors (Honkakoski & Negishi, 2000). Therefore, genetic modification of Caco-2 with nuclear receptor-transfected genes has been employed to improve CYP expression for studies on drug metabolism and drug absorption (Korjamo *et al.*, 2006; Küblbeck *et al.*, 2016).

Caco-2 (passages no. 33 to 43) including wide type (Caco-2/ATCC, HTB-37), human constitutive androstane receptor-transfected Caco-2 (Caco-2/hCAR), and human pregnane X receptor-transfected Caco-2 (Caco-2/hPXR) were examined for expression of CYPs and transporters. All cell-types were subcultured 2 times per week. The cells were cultured in 6-well-plates for one day for an undifferentiated cell model, and in 12-transwell-plates with uncoated PC filter membrane inserts for 21 days for a differentiated cell model. Expression of *CYP1A2*, *CYP2A6*, *CYP2B6*, *CYP2C9*, *CYP2C19*, *CYP3A4*, *CYP3A7*, *ABCG2*, *ABCB1*, *ABCC2*, *SLC15A1*, *SLC16A1*, and *SLCO2B1* mRNAs and CYP activity were determined in both undifferentiated and differentiated Caco-2/ATCC, Caco-2/hCAR, and Caco-2/hPXR. Melatonin (10 μ M), coumarin (5 μ M), bupropion (50 μ M), diclofenac (25 μ M), omeprazole (10 μ M), and midazolam (5 μ M) were used as substrates for *CYP1A2*, *CYP2A6*, *CYP2B6*, *CYP2C9*, *CYP2C19*, and *CYP3A4*, respectively. All substrates were incubated with the cells for 120 minutes, except midazolam for 60 min. For transporter activity, mannitol and antipyrine were used as reference compounds, paclitaxel was used as an *ABCB1* substrate, vinblastine as an *ABCB1* and *ABCC2* substrate, and glycyl-sarcosine as an *SLC15A1* substrate (Küblbeck *et al.*, 2016). Both Caco-2/hCAR and Caco-2/hPXR exhibited greater expression of *CYP1A2*, *CYP2A6*, *CYP2B6*, *CYP2C9*, *CYP2C19*, *CYP3A4*, and *CYP3A7* than wild type Caco-2/ATCC. Particularly, *CYP2C9* showed the highest expression in Caco-2/hCAR while Caco-2/hPXR exhibited the highest *CYP3A4* expression. *PXR* and *CAR* are major CYP-nuclear receptors that are normally present at very low levels or even absent in wild-type Caco-2 cells. Thus, transfection of *PXR* or *CAR* into Caco-2 cells can increase the level and stability of these nuclear receptors, resulting in enhanced CYP expression and capacity (Küblbeck *et al.*, 2016). CYP expression was higher in differentiated Caco-2 cells than in undifferentiated Caco-2, except for *CYP1A2*, which showed no difference in expression between differentiated and undifferentiated cells. *CYP3A7* was similar between differentiated and undifferentiated in all types of Caco-2. All transporters exhibited higher expression in Caco-2/hPXR and Caco-2/hCAR than the wild type, except for *ABCG2* that showed lower expression in Caco-2/hPXR compared to the wild type. *SLCO2B1* and *SLC15A1* were expressed in differentiated Caco-2 higher than in undifferentiated Caco-2 of all types, while *ABCC2* was expressed significantly more in differentiated than in undifferentiated Caco-2/hCAR. In contrast, expression of *ABCB1* and *SLC16A1* in undifferentiated Caco-2 was higher than in differentiated Caco-2. Activity of transporters, in terms of paclitaxel (*ABCB1* activity) and vinblastine (*ABCC2* activity) efflux ratio and glycyl-sarcosine (*SLC15A1* activity) uptake ratio from basal to apical sides, were not different in Caco-2/hPXR and Caco-2/hCAR. Conversely, *ABCB1* and *SLC15A1* activities from apical to basal sides in Caco-2/ATCC were significantly higher than in Caco-2/hPXR and Caco-2/hCAR. *CYP1A2* and *CYP2B6* activities were very low in all types of

Caco-2 while CYP2C activity was 2-fold higher in Caco-2/hPXR than Caco-2/ATCC (Table 3) (Küblbeck *et al.*, 2016).

Three different Caco-2, i.e. Caco-2/ATCC HTB 37 at passages no. 35 to 55, Caco-2/hPXR at passages no. 18 to 32, and Caco-2-transfected murine constitutive androstane receptor (Caco-2/mCAR) at passages no. 12 to 26, were cultured in 12-transwell-plates with uncoated PC filter membrane inserts for 21 days as differentiated models. The cells were incubated with rifampicin (10 µM; an hPXR inducer), 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP, 1 µM; a mCAR inducer), androstrenol (10 µM; a mCAR inhibitor), and 1α,25-dihydroxyvitamin D3 (250 nM; a vitamin D3 receptor activator) for 3, 7, and 14 days (Korjamo *et al.*, 2006). TCPOBOP induced expression of CYP2B6 and CYP2C9 in differentiated Caco-2/mCAR for all treatment periods. Treatment with rifampicin for 14 days significantly increased CYP3A4, CYP2C9, ABCB1, and ABCC2 expression in differentiated Caco-2/hPXR. On the other hand, treatment with 1α,25-dihydroxyvitamin D3 for 14 days dramatically elevated CYP3A4 expression by 900-fold in differentiated Caco-2/ATCC (Table 3) (Korjamo *et al.*, 2006).

It is also important to consider the impact that silencing genes in Caco-2 cells can have in pharmaceutical

research, particularly drug development. A lentivirus transfected knockout Caco-2/ATCC cell line containing ABCB1, ABCG2, and ABCC2 shRNA (small hairpin RNA) and showing an 80% reduction in expression compared to wild-type was used to examine the transport of statin drugs. Simvastatin, lovastatin, atorvastatin, fluvastatin, and rosuvastatin have been reported to be substrates of these transporters, but the major transporter(s) for each statin remain controversial. Statins (each 10 µM) were added to Caco-2 and Caco-2 knockout cells cultured in 12-transwell-plates with coated PC filter membrane inserts and the level of each statin was determined from the basolateral to apical chambers. There was no difference in the level of lovastatin and simvastatin between the ABCB1, ABCG2, or ABCC2-knockout and the control cells, while levels of atorvastatin, fluvastatin, and rosuvastatin were significantly lower in the ABCB1, ABCG2, or ABCC2-knockout cells than in the control. These findings revealed that atorvastatin, fluvastatin, and rosuvastatin were substrates of ABCB1, ABCG2, and ABCC2 transporters, while lovastatin and simvastatin were not (Li *et al.*, 2011). Hence, a gene-knockout Caco-2 model can be a useful tool to clarify intestinal drug transportation and potential drug interactions.

Table 3. Genetically modified Caco-2 cell models

Caco-2 origins	Treatment substances (concentration/incubation time)	Results (compared group or Caco-2 cell types)		References
		Undifferentiated Caco-2 in 6-well-plate	Differentiated Caco-2 in 12-transwell-plate with PC filter membrane insert	
Caco-2/ATCC (Wild type)	NT	↑ ABCB1 ^{b,c,*} , SLCO15A1 ^{b,c,*} , SLC16A1 [*]	↑ CYP2A6 [#] , CYP2B6 [#] , CYP2C9 [#] , CYP2C19 [#] , CYP3A4 [#] ↑ ABCB2, SLCO2B1, SLC15A1 [#] ↑ ABCB1 ^{b,c} , SLCO15A1 ^{b,c} activities ↑ CYP3A4 ^d	Küblbeck <i>et al.</i> , 2016
	1α,25-Dihydroxyvitamin D3 (250 nM/14 days)	N/A		Korjamo <i>et al.</i> , 2006;
Caco-2/hPXR	NT	↑ CYP1A2 ^a , CYP2A6 ^a , CYP2B6 ^a , CYP2C9 ^a , CYP2C19 ^a , CYP3A4 ^a , CYP3A7 ^a ↑ ABCB1 ^{a,*} , ABCC2 ^a , SLCO2B1 ^a , SLC15A1 ^a , SLC16A1 ^{a,*} ↓ ABCG2 ^a	↑ CYP1A2 ^a , CYP2A6 ^{a,#} , CYP2B6 ^{a,#} , CYP2C9 ^{a,#} , CYP2C19 ^{a,#} , CYP3A4 ^{a,#} , CYP3A7 ^a ↑ CYP2C9 ^a , CYP2C19 ^a activities ↑ ABCB1 ^a , ABCC2 ^{a,#} , SLCO2B1 ^{a,#} , SLC15A1 ^{a,#} , SLC16A1 ^a ↓ ABCG2 ^a – ABCB1 ^c , ABCC2 ^c , SLC15A1 ^c activities ↑ CYP3A4 ^d , CYP2C9 ^d , ABCB1 ^d , ABCC2 ^d	Küblbeck <i>et al.</i> , 2016
	Rifampicin (10 µM/14 days)	N/A		Korjamo <i>et al.</i> , 2006;
Caco-2/hCAR	NT	↑ CYP1A2 ^a , CYP2A6 ^a , CYP2B6 ^a , CYP2C9 ^a , CYP2C19 ^a , CYP3A4 ^a , CYP3A7 ^a ↑ ABCB1 ^{a,*} , ABCC2 ^{a,*} , ABCG2 ^a , SLCO2B1 ^{a,#} , SLC15A1 ^{a,#} , SLC16A1 ^{a,*}	↑ CYP1A2 ^a , CYP2A6 ^{a,#} , CYP2B6 ^{a,#} , CYP2C9 ^{a,#} , CYP2C19 ^{a,#} , CYP3A4 ^{a,#} , CYP3A7 ^a ↑ ABCB1 ^a , ABCC2 ^a , ABCG2 ^a , SLCO2B1 ^{a,#} , SLC15A1 ^{a,#} , SLC16A1 ^a – ABCB1 ^b , ABCC2 ^b , SLC15A1 ^b activities ↑ CYP2B6 ^d , CYP2C9 ^d	Küblbeck <i>et al.</i> , 2016
	TCPOBOP (1 µM/3, 14, 21 days)	N/A		Korjamo <i>et al.</i> , 2006

Note: ATCC, American Type Culture Collection; hCAR, human constitutive androstane receptor; hPXR, human pregnane X receptor; mCAR, murine constitutive androstane receptor; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene; NT, non-treated; N/A, data not available; (↑) increase, (↓) decrease, and (–) no change of expression/activity. ^a Result compared to Caco-2/ATCC (wild type), ^b Result compared to Caco-2/hPXR, ^c Result compared to Caco-2/hCAR, ^d Result compared to non-treated group, ^{*} Result compared to differentiated Caco-2 model, [#] Result compared to undifferentiated Caco-2 model.

4. Novel Culturing Methods in Caco-2 Models

A Caco-2 printed 3D-culturing model was established to mimic physiological conditions of the human intestine (Shen, Meng, & Zhang, 2015). Caco-2/ATCC at passages no. 35 to 45 (2×10^5 cells/cm²) were cultured upside down for 21 days on a hanging 3D printed PC membrane insert in a 24-transwell-plate and in a normal 24-transwell-plate with PC filter membrane insert. Marker enzymes on the brush border of intestinal cells, histomorphology, cell viability, and alkaline phosphatase levels were monitored for cell differentiation (Ferrec & Fardel, 2012; Shen *et al.*, 2015). ABCB1 and ABCC2 transporter activities were examined via the efflux ratio of rhodamine 123 (an ABCB1 substrate) and 5-carboxyfluorescein diacetate (5-CFDA; an ABCC2 substrate) after incubation for 0.5, 1, 1.5, and 2 hours (Figure 1) (Shen *et al.*, 2015). Caco-2 on the hanging 3D-printed insert had higher cell viability than those in the normal 24-transwell-plate with no difference in histomorphology. The hanging 3D-printed insert significantly increased levels of alkaline phosphatase and γ -glutamyl transferase by 30 to 100% after incubation for 10 to 21 days. Moreover, the hanging 3D-printed insert culture showed increased ABCB1 and ABCC2 activities as 2- to 7-fold increases in the efflux

ratios of rhodamine 123 and 5-CFDA compared to normal 24-transwell-plate cultures (Table 4) (Shen *et al.*, 2015).

A multi-chamber microfluidic intestinal barrier model was developed to mimic the physiological conditions of human intestine by generating fluid flow in a microfluidic chamber (Tan *et al.*, 2018). Caco-2/ATCC at passages no. 40 to 50 were seeded in a multi-chamber microfluidic platform with thiolene coated Teflon membrane and a 12-transwell-plate with PC filter membrane insert. Histomorphology and cell viability were determined on day 11. ABCB1 activity was determined by incubation of rhodamine 123 with Caco-2 in the microfluidic system for 80 min (Figure 2). Caco-2 cells in the microfluidic culturing system were more than 95% viable after seeding for 11 days. Within three days, Caco-2 cells in the microfluidic culturing system had differentiated into columnar cells close in appearance to healthy human intestinal cells with a height of 40 to 50 μ m. This height was 2-fold that of Caco-2 cultured in 12-transwell-plates for 21 days. ABCB1 is expressed in Caco-2 as an efflux pump, pumping substrates from the basolateral to the apical side. ABCB1 activity was observed in the multi-chamber microfluidic intestinal barrier system after incubation with rhodamine 123 for 80 min (Table 4) (Tan *et al.*, 2018).




Figure 1. Caco-2 culturing on hanging 3D-printed insert model

Table 4. Novel culturing methods for Caco-2 models

Caco-2 origins	Results* (compared culturing methods)	References
Caco-2/ATCC Hanging 3D printed with PC filter membrane insert	<ul style="list-style-type: none"> ↑ Physiological condition, Cell viability ↑ Alkaline phosphatase, γ-Glutamyl transferase ↑ ABCB1, ABCC2 activities 	Shen <i>et al.</i> , 2015
Caco-2/ATCC Multi-chamber microfluidic with thiol-ene coated Teflon filter membrane insert	<ul style="list-style-type: none"> ↑ Physiological fluid flow ↑ ABCB1 activities ↑ Rate of cell growth with intestinal cell appearance in 3 days 	Tan <i>et al.</i> , 2018
Caco-2/ HDDC Gut-on-chip microdevice fabrication (Microchem SU-8 100 mold)	<ul style="list-style-type: none"> ↑ Physiological condition similar to intact intestinal environment ↑ CYP3A4 activity ↑ Rate of cell differentiation into 4 cell types (i.e. basal crypts with extended villi epithelium cell, mucus-secretory cell, enteroendocrine cell, and Paneth cell) within 4 days 	Kim & Ingber, 2013

Note: ATCC, American Type Culture Collection; HDDC, Harvard Digestive Disease Center; NT, Non-treated; 5-CFDA, 5-carboxyfluorescein diacetate; (↑) increase. *Result compared to normal 12/24-transwell-plate.

A novel *in-vitro* model of Caco-2 cells cultured under micro-physiological conditions, or a “gut-on-chip”, has been reported to mimic the shear stress, fluid flow, and circulation physiological conditions of intact intestinal cells. The gut-on-chip system accelerates the differentiation of Caco-2 cells to polarized microvilli-columnar cells, which are similar to intact intestinal cells, faster than in a conventional transwell-plate. Moreover, the fluid flow and shear stress system increases the paracellular permeability of Caco-2 cells, a feature that also appears in *in-vivo* models (Franco, Silva, & Cristofolletti, 2021). Gut-on-chip is a microfabrication of clear silicone rubber forming two layers of microchannels containing a porous polydimethylsiloxane membrane coated with collagen and Matrigel that mimics the environment of the human intestine (Kim & Ingber, 2013; Franco, Silva, & Cristofolletti, 2021). Caco-2 cells (obtained from the Harvard Digestive Disease Center) were seeded into the upper layer of the microdevice and after the cells attached, the device was perfused with fluid flow at 30 mL per hour and fluid shear stress around 0.02 dyne per cm² to both the upper and lower layers, and results were compared to a conventional transwell-plate. The Caco-2 cells in the gut-on-chip model presented four differentiated cell types; basal crypts with extended villi epithelial cells, mucus-secreting cells, enteroendocrine cells, and Paneth cells, within 4 days. In addition, CYP3A4 activity was higher in the gut-on-chip model than in the conventional transwell-plate after 150 hours, as determined by P450-Glo CYP3A4 assay kit (Kim & Ingber, 2013). Interestingly, a 3D perfused gut-on-chip or OrganoPlate three-lane (Mimetas BV) model has been used for co-culture of Caco-2 (intestinal

enterocyte), HT29-MTX-E12 (goblet cell), and THP-1 or MUTZ-3 (immune cell) to examine the anti-inflammatory activity of a compound relative to each cell in the human intestinal inflammatory mechanism (Gijzen *et al.*, 2020). Therefore, the gut-on-chip is a novel human intestine model that has been shown to be useful for studies of drug development, and is a good model to explore human intestinal diseases.

5. Conclusions

Caco-2 shows limited expression of CYPs, particularly for the major CYP3A4 isoform, and requires a long culturing period for differentiation. Hence, several improved Caco-2 models have been developed for examination of drug metabolism and transportation. There are three approaches that have been used, consisting of xenobiotic induced Caco-2 monolayer models, genetically modified Caco-2 models, and novel Caco-2 culturing methods. All three approaches have been established to enhance CYP and transporter expression and shorten the time for cell differentiation. Xenobiotic-induced Caco-2 monolayer models are simple models using typical CYP- or transporter-inducers to enhance expression. CYP3A4, which is normally of very low abundance in Caco-2, can be highly induced by 1 α ,25-dihydroxyvitamin D3 via vitamin D receptor binding, while other CYPs and transporters, e.g. CYP1A1, CYP3A5 and ABCB1, are inducible by typical substrates/inducers such as β -naphthoflavone, Aroclor 1254, and ATRA. These xenobiotic-induced monolayer models show pros and cons.




Figure 2. Caco-2 culturing on multi-chamber microfluidic intestinal barrier model

Table 5. Advantages and disadvantages of Caco-2 models

Model type	Benefits	Limitations
Xenobiotic induced Caco-2 monolayer models	- Easy for culturing and treatment - Less steps of experiment - Economic design	- Low expression of catalytic enzymes - Require long time (2 to 3 weeks) for cell differentiation
Genetic modified Caco-2 models	- Increase expression of CYPs and transporters	- Transfection is complicate. - Require long time (2 to 3 weeks) for cell differentiation
Novel Caco-2 culturing models	- Increase growth rate - Shorten time for cell differentiation - Mimic human intestinal physiology - Increase activity of transporters	- High investment - Few reports on drugs metabolism and transporters

They are simple to conduct in both culturing and treatment phases with economical experimental design, but they require long culturing periods (from 2 to 3 weeks) for cell differentiation. Genetically modified Caco-2 models created by transfection with *PXR* and *CAR* nuclear transporter genes show improved CYP and transporter expression via the up-regulation of their related expression mechanisms. However, these models still require long culturing periods for cell differentiation; and transfection is a complicated, time-consuming process. Novel Caco-2 culturing methods have been developed to mimic human intestinal physiology, increase growth rate, and shorten the period of cell differentiation. Hanging 3D-printed multi-chamber microfluidic and micro-physiological (gut-on-chip) platforms have shown improved cell alignment, and the fluid flow increases growth rate and the activity of efflux transporters and CYP3A4 beyond those in conventional or inserted plate-Caco-2 culturing systems. However, these novel methods require expensive, specialized technological materials, and to date, there are a very few reports using this technology in the context of drug metabolism and transportation (Table 5). In conclusion, an optimal Caco-2 model for drug metabolism and transportation is dependent on the specific aim, which needs to be incorporated into the experimental design of each individual study.

References

- Belin, S., Kaya, F., Burtey, S., & Fontes, M. (2010). Ascorbic acid and gene expression: Another example of regulation of gene expression by small molecules. *Current Genomics*, *11*(1), 52-57. doi:10.2174/138920210790217936
- Borlak, J., & Zwadlo, C. (2003). Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. *Xenobiotica*, *33*(9), 927-943. doi:10.1080/00498250310001614286
- Boulenc, X., Bourrie, M., Fabre, I., Roque, C., Joyeux, H., Berger, Y., & Fabre, G. (1992). Regulation of cytochrome P4501A1 gene expression in a human intestinal cell line, Caco-2. *Journal of Pharmacology and Experimental Therapeutics*, *263*(3), 1471-1478.
- Brück, S., Strohmeier, J., Busch, D., Drozdik, M. & Oswald, S. (2017). Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue. *Biopharmaceutics and Drug Disposition*, *38*(2), 115-126. doi:10.1002/bdd.2025
- Ferrec, E. L., & Fardel, O. (2012). Applications using Caco-2 and TC7 cells for drug metabolism studies. In A. V. Lyubimov (Ed.), *Encyclopedia of Drug Metabolism and Interactions* (pp. 1-16). New Jersey, NJ: John Wiley and Sons.
- Foy, M., Sperati, C. J., Lucas, G. M., & Estrella, M. M. (2014). Drug interactions and antiretroviral drug monitoring. *Current HIV/AIDS Reports*, *11*(3), 212-222. doi:10.1007/s11904-014-0212-1
- Franco, Y. L., Silva, L. D., & Cristofolletti, R. (2021). Navigating through cell-based in vitro models available for prediction of intestinal permeability and metabolism: Are we ready for 3D. *Journal of the American Association of Pharmaceutical Scientists*, *24*(2), 1-8. doi:10.1208/s12248-021-00665-y
- Gijzen, L., Marescotti, D., Raineri, E., Nicolas, A., Lanz, H. L., Guerrero, D., . . . Kurek, D. (2020). An intestine-on-a-chip model of plug-and-play modularity to study inflammatory processes. *SLAS Technology*, *25*(6), 585-597. doi:10.1177/2472630320924999
- Guengerich, F. P. (2013). Cytochrome P450 activation of toxins and hepatotoxicity. In: Kaplowitz N, DeLeve LD. *Drug-Induced Liver Disease* (pp.15-33). Massachusetts, MA: Academic Press.
- Gupta, A., Mugundu, G. M., Desai, P.B., Thummel, K. E., & Unadkat, J. D. (2008). Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors. *Drug Metabolism and Disposition*, *36*(6), 1172-1180. doi:10.1124/dmd.107.018689
- Honkakoski, P., & Negishi, M. (2000). Regulation of cytochrome P450 (CYP) genes by nuclear receptors. *Biochemical Journal*, *347*, 321-337. doi:10.1042/0264-6021:3470321
- Kaminsky, L. S., & Zhang, Q. Y. (2003). The small intestine as a xenobiotic-metabolizing organ. *Drug Metabolism and Disposition*, *31*(12), 1520-1525. doi:10.1124/dmd.31.12.1520
- Kim, H. J., & Ingber, D. E. (2013). Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. *Integrative Biology*, *5*(9), 1130-1140. doi:10.1039/c3ib40126j
- Korjamo, T., Mönkkönen, J., Uusitalo, J., Turpeinen, M., Pelkonen, O., & Honkakoski, P. (2006). Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. *Pharmaceutical Research*, *23*(9), 1991-2001. doi:10.1007/s11095-006-9068-4
- Küblbeck, J., Hakkarainen, J. J., Petsalo, A., Vellonen, K., Tolonen, A., Reponen, P., Forsberg, M. M., & Honkakoski, P. (2016). Genetically modified Caco-2 cells with improved cytochrome P450 metabolic capacity. *Journal of Pharmaceutical Sciences*, *105*(2), 941-949. doi:10.1016/S0022-3549(15)00187-2
- Lea, T. (2015). Caco-2 cell line. In K. Verhoecx, P. Cotter, I. López-Expósito, C. Kleiveland, T. Lea, A. Mackie, T. Requena, D. Swiatecka, & H. Wichers (Eds.), *The Impact of Food Bio-Actives on Gut Health in Vitro and Ex Vivo Models* (pp. 103-110). New York, NY: Springer, Cham.
- Li, J., Volpe, D. A., Wang, Y., Zhang, W., Bode, C., Owen, A., & Hidalgo, I. J. (2011). Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. *Drug Metabolism and Disposition*, *39*(7), 1196-1202. doi: 10.1124/dmd.111.038075
- Li, Q., Sai, Y., Kato, Y., Tamai, I., & Tsuji, A. (2003). Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal

- epithelial cell lines. *Pharmaceutical Research*, 20(8), 1119-1124. doi:10.1023/a:1025076326061
- Maubon, N., Le Vee, M., Fossati, L., Audry, M., Le Ferrec, E., Bolze, S., & Fardel, O. (2007). Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. *Fundamental and Clinical Pharmacology*, 21(6), 659-663. doi:10.1111/j.1472-8206.2007.00550.x
- Meunier, V., Bourrié, M., Berger, Y., & Fabre, G. (1995). The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. *Cell Biology and Toxicology*, 11(3-4), 187-194. doi:10.1007/BF00756522
- Mukhopadhyay, I., Murray, G. I., Berry, S., Thomson, J., Frank, B., Gwozdz, G., . . . Hijazi, K. (2016). Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization. *Journal of Antimicrobial Chemotherapy*, 71(2), 372-386. doi:10.1093/jac/dkv335
- Notas, G., Nifli, A.P., Kampa, M., Pelekanou, V. Alexaki, V. I., Theodoropoulos, P., . . . Castanas, E. (2012). Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. *The Journal of Nutritional Biochemistry*, 23(6), 656-666. doi:10.1016/j.jnutbio.2011.03.010
- Natoli, M., Leoni, B. D., D'Agnano, I., D'Onofrio, M., Brandi, R., Arisi, I., . . . Felsani, A. (2011). Cell growing density affects the structural and functional properties of Caco-2 differentiated monolayer. *Journal of Cellular Physiology*, 226(6), 1531-1543. doi:10.1002/jcp.22487
- Rousset, M. (1986). The human colon carcinoma cell lines HT-29 and Caco-2: Two in vitro models for the study of intestinal differentiation. *Biochimie*, 68(9), 1035-1040. doi:10.1016/S0300-9084(86)80177-8
- Sambuy, Y., Angelis, I. D., Ranaldi, G., Scarino, M. L., Stamatii, A., & Zucco, F. (2005). The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. *Cell Biology and Toxicology*, 21(1), 1-26. doi:10.1007/s10565-005-0085-6
- Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997). Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. *Molecular Pharmacology*, 51(5), 741-754. doi:10.1124/mol.51.5.741
- Shen, C., Meng, Q., & Zhang, G. (2015). Design of 3D printed insert for hanging culture of Caco-2 cells. *Biofabrication*, 7(1), 015003. doi:10.1088/1758-5090/7/1/015003
- Sun, D., Lennernas, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., . . . Amidon, G. L. (2002). Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. *Pharmaceutical Research*, 19(10), 1400-1416. doi:10.1023/a:1020483911355
- Sun, H., Chow, E. C., Liu, S., Du, Y., & Pang, S. K. (2008). The Caco-2 cell monolayer: usefulness and limitations. *Expert Opinion on Drug Metabolism and Toxicology*, 4(4), 395-411. doi:10.1517/17425255.4.4.395
- Tan, H. Y., Trier, S., Rahbek, U. L., Dufva, M., Kutter, J. P., & Andresen, T. L. (2018). A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies. *PLoS One*, 13(5), e0197101. doi:10.1371/journal.pone.0197101
- Vaessen, S. F., van Lipzig, M. M., Pieters, R. H., Krul, C. A., Wortelboer, H. M., & van de Steeg, E. (2017). Regional expression levels of drug transporters and metabolizing enzymes along the pig and human intestinal tract and comparison with Caco-2 cells. *Drug Metabolism and Disposition*, 45(4), 353-360. doi:10.1124/dmd.116.072231
- Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, 138(1): 103-141. doi:10.1016/j.pharmthera.2012.12.007